Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: Some concerns

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|7|1085-1085

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.7, 2014-04, pp. : 1085-1085

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?

By  

THE BREAST JOURNAL, Vol. 21, Iss. 5, 2015-09 ,pp. : 514-519

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

Early DNA damage response in residual carcinoma in situ at ductal stumps and local recurrence in patients undergoing resection for extrahepatic cholangiocarcinoma

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 20, Iss. 3, 2013-03 ,pp. : 362-369

John Wiley & Sons Inc

Access to resources Recommend Favorite

Breast Cancer Chemoprevention among High‐risk Women and those with Ductal Carcinoma In Situ

By  

THE BREAST JOURNAL, Vol. 21, Iss. 4, 2015-07 ,pp. : 377-386

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ductal Carcinoma in situ of the Breast: Diagnosis and Management

By  

Oncology Research and Treatment, Vol. 26, Iss. 6, 2004-01 ,pp. : 588-595

Karger

Access to resources Recommend Favorite